Cereno Scientific solidifies CS1’s patent protection with new European patent
Cereno Scientific (XSAT: CRNO B) today announced that the European Patent Office (EPO) has granted a patent for CS1’s second patent family. The new patent adds to the existing intellectual property rights (IPR) for this strategically important market which now covers two of Cereno’s three patent families.
“I am pleased to see a further strengthening of our patent protection for CS1 in Europe, one of the largest markets for pharmaceutical products globally. Adding to our patent protection in Australia, Canada, Japan, Russia and the US, I believe we are building a strong IPR position for CS1,” said Sten R. Sörensen, CEO at Cereno Scientific.
The granted European patent is part of Cereno’s second patent family related to drug candidate CS1 titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation”. It has been given patent number EP3203997 and will be valid through 2035, with the possibility of a patent extension of up to five years.
The patent grant followed a coordinated search and evaluation conducted by the EPO on behalf of all member countries. Now follows a registration process of national patents in the individual EPO member countries selected by Cereno.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The CS585 program consists of stable, selective, and potent IP (prostacyclin) receptor agonists and the CS014 program comprises HDAC inhibitors with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.